

Selected Clinical Research Protocols Relating to Chronic Myelogenous Leukemia (CML)

More information on the trials listed below is available at PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at www.cancer.gov. A searchable Web site developed by the National Library of Medicine is also available at clinicaltrials.gov.

Phase III

Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase CML
NCT00481247

Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
NCT00471497

Compare Bosutinib to Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
NCT00574873

Nilotinib Versus Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR
NCT00760877

Suboptimal Study Comparing Nilotinib and Imatinib
NCT00802841

Phase II

Randomized Study of Imatinib Mesylate at Standard Versus Increased Dose or Dasatinib in Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00070499

Pilot Study of PHA-739358 in Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
NCT00335868

Randomized Study of Imatinib Mesylate, Interferon- α , and Sargramostim (GM-CSF) Versus Ima-

tinib Mesylate and GM-K562 Cell Vaccine in Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Achieved a Complete Cytogenetic Response to Single-Agent Imatinib Mesylate
NCT00363649

Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00129740

Study of Subcutaneous Homoharringtonine in Patients With Imatinib Mesylate-Resistant, Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia With the T315I BCR-ABL Gene Mutation
NCT00375219

Study of Nilotinib and Imatinib Mesylate in Patients With Philadelphia Chromosome- and BCR-ABL-Positive Early Chronic Phase Chronic Myelogenous Leukemia
NCT00769327

Study of Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myelogenous Leukemia
NCT00809211

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
NCT00114959

Open Label Study of Subcutaneous Homoharringtonine in Patients With Advanced CML
NCT00462943

Nilotinib as First-Line Treatment of Ph+ CML in Early Chronic Phase
NCT00481052

Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Accelerated Phase) Subjects
NCT00529763

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
NCT00644878

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation
NCT00750659

Phase I/II

Pilot Study of Imatinib Mesylate and/or Nilotinib After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
NCT00702403

Study Evaluating SKI-606 in Philadelphia Chromosome Positive Leukemias
NCT00261846

Study Evaluating SKI-606 in Japanese Subjects With Philadelphia Chromosome Positive Leukemias
NCT00811070

Phase I

Study of Tipifarnib and Bortezomib in Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
NCT00383474

Study of Histone Deacetylase Inhibitor LBH589 and Imatinib Mesylate in Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia in Cytogenetic Remission
NCT00686218

Study of Dasatinib and Vorinostat as Front-Line Therapy in Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT00816283

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
NCT00464113

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
NCT00732186

Study Evaluating the Pharmacokinetics (PK) and Safety of Bosutinib in Subjects With Liver Disease and in Healthy Subjects
NCT00759837

The following trial is currently being conducted at Moffitt Cancer Center. For additional information about this trial, and others, please visit MOFFITT.org or call Cheryl Maker in the Clinical Research Department at (813) 745-4106 or e-mail cheryl.maker@moffitt.org.

Phase I

Dose-Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of XL228 Administered Intravenously to Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia (Ph+ ALL)
MCC #15244